Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of recombinant human growth hormone (rhGH) and metformin. This combination has been studied for its effects on glucose metabolism, body composition, and potential anti-aging properties. The metformin component is specifically included to counter the diabetogenic (glucose-raising) effects of growth hormone. The combination has been investigated in the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial for thymus regeneration and potential biological age reversal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human growth hormone + metformin.